Cellectar Biosciences to Present at IWWM Featuring Iopofosine I 131

Company Overview - Cellectar Biosciences, Inc. (CLRB) announced two presentations regarding the treatment of Bing-Neel Syndrome (BNS) with iopofosine I 131 and a review of the CLOVER WaM pivotal study of iopofosine I 131, to be presented at the 12th International Workshop on Waldenstrom's Macroglobulinemia (IWWM) on October 17, 2024, in Prague, Czech Republic [1][3] Product Information - Iopofosine I 131 is a potential first-in-class cancer-targeting agent that can cross the blood-brain barrier and has shown clinical activity in multiple hematologic malignancies, including relapsed/refractory primary CNS lymphoma [2] - The treatment of BNS, a rare and life-threatening complication of Waldenstrom's Macroglobulinemia (WM), requires agents that can penetrate the blood-brain barrier [4] Clinical Developments - At the IWWM, a case study will be presented demonstrating complete CNS clearance in a relapsed/refractory BNS patient treated with iopofosine I-131 [3] - The CLOVER WaM pivotal study, which is the first and largest WM study in a highly refractory patient population, has shown a 98% disease control rate and an 80% overall response rate with just four doses of iopofosine monotherapy [7] Strategic Partnerships - In July 2024, Cellectar Biosciences entered into a strategic partnership with City of Hope Cancer Center to focus on the clinical development of iopofosine I 131 in mycosis fungoides, a rare form of non-Hodgkin's lymphoma [8] Market Prospects - The WM treatment market is expected to grow at a CAGR of 5.2% from 2022 to 2027, driven by increasing prevalence of WM cases, drug approvals, and a rising geriatric population [5][6]